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Myogenesis is accompanied by the activation of two developmental myosin heavy chains (MyHCs), embryonic and perinatal, followed by a
dramatic decrease in their expression during early postnatal life. The pathways that control the transcription of these genes have not been
previously determined. In this study, we identified cis-acting elements and trans-acting factors that regulate the expression of these two
developmental MyHCs in the mouse. Between 800 and 1000 bp of proximal promoter sequence is sufficient to drive muscle-specific expression in
cell culture. Further, these same regions contain sequences that confer downregulation in postnatal life in vivo. For the embryonic MyHC gene, the
region between −791 bp and −626 bp contains the majority of activating elements. In the proximal promoter regions of both genes, we identified
two E-box elements that work in conjunction to activate transcription, but only the embryonic MyHC E-boxes bind a complex containing MyoD.
In addition, our results reveal activation by calcineurin that is transduced only partially by its conventional downstream effectors, MEF2 and
NFAT. Some common features are shared between the promoters of these two genes; however, the mechanisms of their regulation appear distinct.
© 2006 Elsevier Inc. All rights reserved.Keywords: Developmental myosin; Skeletal muscle; Myogenic regulatory factors; Calcineurin; PromoterIntroduction
The myosin proteins responsible for muscle contraction in
mammals constitute a class of at least eight isoforms, each
encoded by its own gene (Weiss and Leinwand, 1996). Six of
these myosin heavy chain (MyHC) genes are expressed
predominantly in skeletal muscle and are organized in a
conserved cluster on chromosome 17 in humans and 11 in mice
(Weiss et al., 1999). The MyHC isoforms each have distinct
biochemical characteristics, and the physiological properties of
a muscle are based in part on which isoforms are predominantly
expressed (Pette and Staron, 1997). Temporal and spatial
regulation of each of the different skeletal MyHCs can therefore
lead to functional differences in muscles.
Each MyHC gene exhibits a pattern of expression according
to muscle type and developmental time point. One slow isoform
(I) and three fast isoforms (IIA, IID, and IIB) are expressed in a⁎ Corresponding author. Fax: +1 303 492 8907.
E-mail address: leslie.leinwand@colorado.edu (L.A. Leinwand).
1 Present address: Department of Integrative Physiology, University of
Colorado, Boulder, Colorado 80309-0354, USA.
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.02.049mosaic pattern in skeletal muscle throughout adult life. In
contrast, two MyHC isoforms are only expressed during
development and in regenerating adult muscle fibers. Embry-
onic MyHC (MyHC-emb) and perinatal MyHC (MyHC-peri)
are expressed sequentially during development with MyHC-
emb transcript first detected at 9.5 days postcoitum (dpc) and
MyHC-peri transcript at 10.5 dpc in the mouse (Lyons et al.,
1990). Peak expression of MyHC-emb occurs at around 15 dpc,
while the MyHC-peri transcript reaches its peak about 5 days
after birth (Allen and Leinwand, 2001; Lu et al., 1999; Lyons et
al., 1990). Expression of both developmental myosins is then
downregulated until they account for less than 1% of total
MyHC protein at 20 days postnatal (Allen and Leinwand, 2001;
Lu et al., 1999). The developmental MyHCs are not detected in
normal adult muscles (Allen and Leinwand, 2001; Lu et al.,
1999) but are re-expressed transiently in muscles regenerating
after injury or disease (d'Albis et al., 1988).
The MyHC genes are transcriptionally regulated (Cox and
Buckingham, 1992), and several key pathways have been
implicated in the transcriptional control of muscle-specific
genes including some of the MyHCs. The myogenic regulatory
factor (MRF) family of transcription factors and the calcineurin
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activated T cells (NFAT) and myocyte enhancer factor 2
(MEF2), are two groups of molecules that provide good
candidates for the regulation of the developmental MyHCs.
MRFs are a family of basic helix–loop–helix (bHLH)
proteins that induce the transcription of many muscle-specific
genes. Four members of the MRF family have been identified to
date: MyoD, myogenin, Myf5, and MRF4. Members of this
family induce expression of not only sarcomeric proteins but also
upstream regulatory proteins and can thus cause the myogenic
conversion of many non-muscle cells when ectopically
expressed (Choi et al., 1990; Davis et al., 1990; Tapscott et al.,
1988). Myf5, MyoD, and myogenin transcripts are first detected
between 8 dpc and 10.5 dpc and therefore could influence
developmental MyHC expression (Ott et al., 1991; Sassoon et
al., 1989). Like all bHLH proteins, the MRFs recognize the E-
boxmotif, which has a core sequence of CANNTG (Lassar et al.,
1989). E-boxes found in the promoter regions and enhancers of
many muscle-specific genes including myosin light chain 1/3
(Ceccarelli et al., 1999; Wentworth et al., 1991), MyHC-IIB
(Wheeler et al., 1999), and muscle creatine kinase (Lassar et al.,
1989; Weintraub et al., 1990) are critical for expression.
The Ca2+ induced calcineurin pathway is another candidate
for the regulation of the developmental myosins, given its
apparent role in myocyte differentiation and muscle regenera-
tion (Abbott et al., 1998; Friday et al., 2000; Sakuma et al.,
2003). Calcineurin (Cn) is a phosphatase that dephosphorylates
NFAT, allowing it to translocate into the nucleus where it
cooperates with other factors to induce transcription of target
genes (Chin et al., 1998; Timmerman et al., 1996). In muscle,
MEF2, which is also activated by calcineurin (Wu et al., 2001),
has been shown to act cooperatively with NFAT to regulate
activity of the myoglobin promoter and the troponin I (slow
form) enhancer (Chin et al., 1998; Wu et al., 2000).
Cyclosporine A, a specific inhibitor of calcineurin, also inhibits
the differentiation of muscle cells in culture, indicating a role in
the regulation of early muscle genes (Abbott et al., 1998).
We have previously shown that MRFs and the calcineurin
pathway can differentially influence activity of the three adult
fast MyHC promoters (Allen et al., 2001). MRFs activate the
promoter of IIB, the fastest adult isoform, while constitutively
active calcineurin preferentially activates the promoter of IIA,
the slowest of the three isoforms. From evidence in chick
embryos (Breckler and Winters, 1988; Kalamkarova et al.,
1988), the developmental isoforms are considered to be slower
in terms of ATPase activity than the adult isoforms and,
therefore, may have regulatory input similar to the slower adult
isoforms. However, novel mechanisms likely exist for tran-
scriptional activation and inactivation of the developmental
MyHCs since they have a unique temporal expression.
Transcriptional control of the developmental MyHCs has not
been studied thoroughly. The activities of various lengths of rat
and human MyHC-emb promoter sequences have been
assessed, but specific cis-elements and their trans-acting factors
have, for the most part, not been determined (Bouvagnet et al.,
1987; Konig et al., 2002). One study found a positive cis-
element in the rat MyHC-emb promoter that binds anundescribed protein complex found in C2 myoblasts and
myotubes, as well as HeLa cells (Yu and Nadal-Ginard, 1989).
No studies have characterized the perinatal MyHC promoter
region or the factors that act on it.
In the present study, we sought to identify the cis-elements
and trans-factors involved in the transcriptional regulation of the
two developmental MyHCs. We isolated a portion of the
proximal upstream promoter sequence for both genes that was
sufficient to direct muscle-specific expression of a reporter gene
in cell culture. These same sequences also contained elements
responsible for decreased expression during postnatal life in
vivo. Both of these promoters were responsive to MyoD and
calcineurin overexpression in muscle cells. Deletion analysis
identified a different region in each promoter that was essential
for expression and contained three E-boxes. Mutational analysis
revealed that the two proximal E-boxes in each sequence were
necessary for full activity, while binding studies showed that
only theMyHC-emb proximal E-boxes were able to bindMyoD.
Methods
Plasmids and DNA probes
All luciferase reporter constructs were made by replacing the cytomegalo-
virus (CMV) promoter of the VR1255 vector (Vical, San Diego, CA) with a
segment of the mouse MyHC-emb or MyHC-peri promoter using the MscI-
SacII endonuclease restriction sites. All MyHC-emb and MyHC-peri promoter
sequences contained 13 bp or 9 bp, respectively, downstream of the
experimentally determined major transcriptional start site for that gene (B.K.
Dennehey and K.S. Krauter, personal communication). The MyHC-emb
promoter contains a TATA box sequence (TATAAAAG) that begins 29 bases
upstream of the major start site, and the first T in that sequence has therefore
been designated base −29. Full-length and truncated constructs contained
MyHC-emb sequences from −791 to +14 (EmbWT), −626 to +14 (Emb600), or
−389 to +14 (Emb360). A MyHC-emb minimal promoter containing only the
TATA box and 34 bp of downstream sequence (−29 to +14) was also
constructed. The distal + min construct was created by placing the sequence
from −791 to −627 directly upstream of the minimal promoter. To accomplish
this, the sequence from −626 to −30 was removed by inverse PCR and replaced
with a SpeI restriction site. Mutant constructs were made from the full length
EmbWT plasmid using PCR-mediated point mutagenesis. The E-box starting at
−758 bp was mutated from CATCTG to CATCCA (EE1), the E-box starting at
−684 bp was mutated from CAGCTG to CAGCAT (EE2), and the E-box
starting at −632 bp was mutated from CAGCTG to GCGCTG (EE3). Additional
E-boxes in the MyHC-emb promoter sequence were mutated to create a
construct with no E-boxes in the promoter region (EnoE). In addition to
mutations in E-boxes 1–3, the following mutations of E-boxes at the indicated
positions were also included in the EnoE construct: CAACTG to GCACTG
starting at −466, CAACTG to GGACTG starting at −367, CAAGTG to
CAAGAC starting at −346, CAGCTG to GTGCTG starting at −330, and
CAGTTG to GCGTTG starting at −191. TheMyHC-peri promoter also contains
a TATA box sequence (TATATAAG) that begins 29 bases upstream of the major
start site, and the first T in that sequence has therefore been designated base −29.
Full-length and truncated constructs contained MyHC-peri sequences from
−983 to +9 (PeriWT), −599 to +9 (Peri600), or −356 to +9 (Peri360). Mutant
constructs were made from the PeriWT plasmid using a PCR-mediated point
mutagenesis method. The E-box starting at −351 was mutated from CATCTG to
ATTCTG (PE1), the E-box starting at −122 was mutated from CAAATG to
CAAAGC (PE2), the E-box starting at −84 was mutated from CAAGTG to
ATAGTG (PE3), and the MEF2 site located at −189 was mutated from
TTATTTATAG to TTACGTATAG (PMEF2mut).
A thymidine kinase-renilla luciferase vector (pRL-TK; Promega) was used
as an internal transfection control. The RSV-MyoD expression vector was a gift
from Harold Weintraub, the CMV-Myf5 expression vector a gift from Stephen
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constitutively active calcineurin expression vectors as well as the NFAT sensor,
GFP-SPRIEIT, and GFP-SPAIAIA plasmids were all kindly provided by Eric
Olson. Plasmid DNA was purified using the QIAfilter Plasmid Midi Kit
(QIAGEN) for use in cell culture experiments or purified by cesium chloride
gradient for in vivo injections.
Duplex probes for mobility shift assays were made from oligonucleotides
ordered from Integrated DNA Technologies, Inc. and had the following sense
sequences (E-box bolded, mutated bases underlined):EE1WTFig. 1. Endogen
C2C12 cells duri
however, IIA ha
to the top band.5′ GAA ATG ACA GCA TCT GTT AGG CGATAC C 3′
EE1mut 5′ GAA ATG ACA GCA TCC ATT AGG CGATAC C 3′
EE2WT 5′ CCT ATC TAG GCT GGC AGC TGG CCT TTC CTA 3′
EE2mut 5′ CCT ATC TAG GCT GGC AGC ATG CCT TTC CTA 3′
EE3WT 5′ GGC CCC TAA GCA GCT GTC ACT GTG AA 3′
EE3mut 5′ GGC CCC TAA GGC GCT GTC ACT GTG AA 3′
PE1WT 5′ GAG TTG CTG GGC ATC TGATCT TTG GCA 3′
PE1mut 5′ GAG TTG CTG GGA TTC TGATCT TTG GCA 3′
PE2WT 5′ CCG AAG ATG CCA AAT GTT GCT ACA AA 3′
PE2mut 5′ CCG AAG ATG CCA AAG CTT GCT ACA AA 3′
PE3WT 5′ GGT TCC TGT TGC CAA GTG TTT GGC CCT 3′
PE3mut 5′ GGT TCC TGT TGC ATA GTG TTT GGC CCT 3′Cell culture and transfections
C2C12 and L cells were obtained from the American Type Culture
Collection. Mouse C2C12 myoblasts were grown on 0.5% gelatin coated dishes
in DMEM (Gibco-BRL, cat #12100-061) supplemented with 1.5 g/l sodiumous MyHC protein expression timecourse. (A) Western blot of all sar
ng differentiation was first separated by high-resolution gel electro
s previously been shown to be very low in these cells (Allen and Leinw
(B) Relative levels of the MyHC isoforms as a percentage of the tobicarbonate and 20% FBS (Hyclone). All transfections were carried out on 24-
well plates with cells that were 70–80% confluent. Cells were transfected as
described previously (Allen et al., 2001). When the cells became confluent (12–
24 h after transfection), cells were placed in differentiation medium (DMEM
plus 1.5 g/l sodium bicarbonate and 1% horse serum (Gibco-BRL)). Myoblasts
were harvested at confluence and myotubes and L cells were harvested 3 days
after transfection. A dual luciferase assay system (Promega) was used to
measure firefly and renilla luciferase values. Briefly, cells were rinsed in
phosphate-buffered saline and then lysed in 1× Passive Lysis Buffer (Promega).
10 μl of the cell lysate was used to assay for both firefly (reporter constructs) and
renilla (internal control) luciferase activity using a standard luminometer.
Normalized values for reporter activities were calculated as the ratio between
firefly luciferase and renilla luciferase activities in all transient transfection
experiments with the exception of the NFAT inhibitor experiments where only
the firefly luciferase value is shown.
Electrophoretic mobility shift assays
C2C12 nuclear extracts were prepared essentially as described in Dignam et
al. (1983). Complimentary oligos were annealed to create a 3′ overhang that was
filled and labeled by incorporation of two α32P-dCTP nucleotides using Klenow
enzyme. Probes were incubated for 30 min at room temperature with 9 μg of
C2C12 nuclear extract and 1 μg poly dI–dC (Amersham) in 1× binding buffer
(10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 1.25% Ficoll).
Samples were loaded onto a 4% polyacrylamide gel and run in 0.5× TBE buffer.
In competition or supershift assays, a 50× excess of unlabeled probe or 0.5 μg
antibody was added to the reaction mixture. Antibodies against myogenin (M-
225), MRF4 (Myf6 242), and Myf5 (c-20) were obtained from Santa Cruz
Biotechnology. The NCL-MyoD1 antibody was obtained from Novocastra.comeric MyHCs over the course of C2C12 differentiation. Protein collected from
phoresis. The band corresponding to IIA is masked by the Embryonic band,
and, 2001; Allen et al., 2001) and, therefore, is making a negligible contribution
tal MyHC present in each sample.
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Protein was collected fromC2C12 cells just before transition to differentiation
media (day 0) and at specified times after the transition to differentiation media.
Cells were scraped into myosin extraction buffer (Butler-Browne and Whalen,
1984) and incubated on ice for 1 h. Cell debris was removed by centrifugation,
and total protein concentration was determined using the Bradford Assay (Bio-
Rad). For each sample, 5 μg of total protein was loaded onto an 8% acrylamide
gel according to the protocol by Talmadge and Roy (1993) with 2-
mercaptoethanol added to the upper running buffer at a final concentration of
10 mM (Fritz et al., 1989). The high-resolution gel was run at 90 V for 30 h at
4°C. Proteins from the gel were then blotted onto Hybond-P PVDF membrane
(Amersham Biosciences) in a mini-blot apparatus at 30 V for 16 h at 4°C. All
sarcomeric myosins were visualized using the F59 antibody (Miller et al., 1989),
goat anti-mouse secondary antibody conjugated to horseradish peroxidase (Bio-
Rad), and the Western Lightning Chemiluminescence Reagent (Perkin Elmer
Life Sciences). Bands were identified based on previous reports of MyHC
migration order (Agbulut et al., 2003; Allen and Leinwand, 2001; Talmadge and
Roy, 1993) and quantified using ImageQuant software (Molecular Dynamics).
In vivo injection of plasmids
Wild-type and double mutant plasmid constructs were injected into the
hindlimbs of postnatal mouse pups at 1 dpn. Adult mice (2 months old) were
injected directly in the tibialis anterior (TA) muscle. A pRL-CMV (Promega)
plasmid was used as a control for uptake efficiency. The sterile 167 mM NaCl
injection solution contained the experimental plasmid at 1 μg/μl and pRL-CMV
plasmid at 42 ng/μl. Newborns were anesthetized by chilling on ice while adults
were anesthetized by halothane inhalation. 25 μl of sterile injection solution plus
plasmidwas injected into the hindlimb of pups, and 30μl was injected directly into
the TAmuscle of adults. Four days postinjection, anesthetizedmicewere sacrificed
by cervical dislocation (adults) or decapitation (pups). Muscles of the entire
hindlimb (pups) or the TA (adults) were dissected from mice and homogenized in
500 μl of buffer containing 25 mMGlygly pH 7.8, 15 mMMgSO4, 4 mM EGTA
pH8.0, and 1mMdithiothreitol. Samples were clarified by centrifugation and used
in the dual luciferase assay as described above. All procedures involving live mice
were performed in accordance with institutional guidelines.Fig. 2. Activity of MyHC-emb and MyHC-peri proximal promoters in muscle
and non-muscle cells. EmbWT and PeriWT plasmids were transfected into
C2C12 cells (A) and non-muscle L cells (B) along with pRL-TK as a transfection
control. Firefly luciferase values from each sample were first normalized to
renilla luciferase activity and results are expressed as the mean ± SE.
*Significantly different from myoblasts (P < 0.0001); †significantly different
from perinatal (P < 0.0001).Results
Endogenous MyHC protein levels in C2C12 cells
To determine relative expression levels of the MyHCs during
C2C12 cell differentiation, Western blots were performed on
total protein from cells at specific times after the addition of
differentiation media (Fig. 1). Embryonic MyHC and slow (type
I) MyHC appear at time 0, before differentiation media are
added, indicating that the myocytes had begun to differentiate
on their own upon reaching confluence. Perinatal, IIB, and IID
MyHCs appear 12 h after the addition of differentiation media
and generally increase over the course of differentiation.
MyHC-emb remains the dominant isoform throughout the
timecourse and ranges from 7- to 2-fold more abundant than
MyHC-peri as differentiation progresses.
Proximal promoter sequences are sufficient for muscle-specific
expression
Previous studies of the three adult fast MyHC proximal
promoters indicated that 1 kb or less was sufficient to confer
muscle-specific expression that mimicked endogenous relative
levels of protein (Allen et al., 2001). To identify promotersequences with similar properties for the mouse developmental
MyHCs, the sequence from −791 to +14 of MyHC-emb or the
sequence from −983 to +9 of MyHC-peri driving the expression
of luciferase (constructs EmbWT and PeriWT, respectively) was
tested for activity in myogenic C2C12 cells and non-muscle L
cells. The activities of the EmbWT and PeriWT promoters were
significantly higher in differentiated myotubes than in prolifer-
ating myoblasts (Fig. 2A). The activity of EmbWT was
significantly higher than PeriWT in bothmyoblasts andmyotubes
which is consistent with the relative levels of endogenous protein
in these cells (Fig. 1). In contrast, activity for both promoters was
extremely low in L cells (Fig. 2B). Taken together, these results
indicate that these promoter sequences contain the regulatory
elements sufficient for muscle-specific expression.
Promoters respond to MyoD, Myf5, and calcineurin
To identify signaling pathways controlling transcription of
MyHC-emb and MyHC-peri, the EmbWT and PeriWT
constructs were co-transfected into C2C12 cells along with
plasmids overexpressing a number of factors known to regulate
muscle-specific genes (Fig. 3A). Of those tested, only MyoD
and constitutively active calcineurin (caCn) significantly
increased the activity of both promoters. EmbWT activity was
induced 5.5- and 3.4-fold while PeriWT activity was induced
26.9- and 11.8-fold by MyoD and caCn, respectively. The
greater fold increase in activation of PeriWT by both of these
co-transfectants relative to the fold increase of EmbWT activity
is likely due to the higher basal activity of EmbWT in these cells
(Fig. 2A). Myf5 also increased EmbWTactivity significantly by
Fig. 3. Responsiveness of promoters to overexpression of known muscle regulatory proteins in cell culture. EmbWTand PeriWTwere co-transfected individually with
overexpression plasmids for MyoD, Myf5, constitutively active calcineurin (caCn), constitutively nuclear NFAT (cnNFAT), MEF2C, or cnNFATandMEF2C in C2C12
cells (A) and in L cells (B). Results are expressed as fold change in activation compared to the β-galactosidase overexpression control. *Significantly different from β-
gal overexpression (P < 0.05); **significantly different from β-gal overexpression (P < 0.0001).
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increased the promoter activities of EmbWT and PeriWT, two
downstream targets of calcineurin, NFAT and MEF2, had no
effect on promoter activity when individually co-transfected
with either EmbWT or PeriWT. Since NFAT and MEF2 have
been shown to work cooperatively to activate transcription (Wu
et al., 2000), we co-transfected both NFAT and MEF2
expression plasmids together with the EmbWT or PeriWT
constructs. This resulted in a modest, but significant, activation
of EmbWT (1.8-fold) but not of PeriWT (Fig. 3A).
All of the factors tested by overexpression are present at
moderate to high levels in differentiating C2C12 cells (Dedieu et
al., 2002; Delling et al., 2000; Miller, 1990; Ornatsky and
McDermott, 1996). Since endogenous levels of these factors
may preclude any additional activation of the promoters, co-
transfections were also carried out in non-muscle L cells to
specifically assess the promoters' responsiveness to these
regulatory factors (Fig. 3B). MyoD increased MyHC-emb andMyHC-peri promoter activity by 14- and 6-fold respectively in
L cells while caCn had no effect, suggesting that calcineurin
requires other muscle-specific factors to activate these promo-
ters. Myf5 activated expression of the pRL-TK control plasmid.
For this reason, when the data were normalized, it appeared that
Myf5 actually inhibited the activity of the promoters (Fig. 3B).
However, when the results are not normalized, this effect is no
longer seen, and it appears that Myf5 does not significantly
influence promoter activity. Overexpression of cnNFAT or
MEF2 increased EmbWT activity by 1.5-fold and 2-fold,
respectively. Overexpression of both factors simultaneously
increased EmbWT activity by 2-fold and PeriWT by 1.5-fold.
Conserved motifs in the proximal promoter regions
Putative transcription factor binding sites were identified in
the promoter sequences using the MATInspector program with
the TRANSFAC database (Quandt et al., 1995;Wingender et al.,
Fig. 4. Conserved putative transcription factor binding motifs. MATInspector
was used with the TRANSFAC database to identify putative binding motifs.
Motifs conserved in human, rat, andmouseMyHC-emb sequences or human, pig,
and mouse MyHC-peri sequences are shown. Scale in base pairs. Arrowheads
indicate the boundaries of truncations tested in Fig. 5. E-boxes are labeled.
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and mouse (MyHC-emb) or human, pig, and mouse (MyHC-
peri) are shown in Fig. 4. Three E-boxes and one NFAT binding
site are positioned in the distal region of MyHC-emb, from −791
to −627. Three conserved E-boxes and one MEF2 binding site
are located in the proximal region of the MyHC-peri promoter.
Other conserved binding motifs are also shown (Fig. 4).
Promoter truncations reveal important regulatory sequences
In order to determine which regions of the promoter
sequences have specific regulatory functions, a series of deletionFig. 5. Activity of truncated promoter constructs in C2C12 cells. (A) Fold change in no
compared to EmbWT. (B) Fold change in normalized activities (firefly/renilla) of t
different from WT (P < 0.0001); †significantly different from min (P < 0.0001).constructs in which the promoter sequence was truncated at the
5′ endwere tested in C2C12 cells. Deletion of bases−791 to−627
(Emb600) resulted in a 90% decrease in activity compared to
EmbWT, and additional deletion of bases −791 to −340
(Emb360) did not have any further significant effect (Fig. 5A).
Thus, sequences between −791 and −627 appear to be necessary
for the activity of this promoter. However, this segment is not
sufficient to drive full expression when placed upstream of a
minimal promoter containing only the MyHC-emb TATA-box
and downstream bases to +14 (distal + min, Fig. 5A) indicating
that some of the intervening promoter sequences may be
necessary to work in conjunction with the upstream segment.
These findings are consistent with a recent study of the MyHC-
emb promoter that revealed, through Bayesian analysis, two
regions of likely conservation between human and mouse within
the proximal 1 kb of this promoter that correspond to the
sequences distal to −600 bp and proximal to −300 bp (Konig et
al., 2002). Konig and colleagues also showed that the distal
sequences of the human MyHC-emb promoter must work with
the specific proximal sequences of the promoter, in agreement
with the results presented here (Fig. 5A).
In contrast, truncation of the perinatal MyHC promoter by
deleting bases −983 to −600 (Peri600) or −983 to −357
(Peri360) had no significant effect on promoter activity (Fig.
5B). This suggests that the major elements responsible for
activity of the perinatal MyHC promoter are located in the
proximal 356 bp. Bayesian analysis of the MyHC-peri promoter
showed likely conservation between human and mouse only in
the proximal region of the promoter that corresponds to our
Peri360 promoter region (Konig et al., 2002).rmalized activities (firefly/renilla) of truncated MyHC-emb promoter constructs
runcated MyHC-peri promoter constructs compared to PeriWT. *Significantly
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but not EmbWT
To understand the role of NFAT in the caCn activation of
these promoters, we used an inhibitor of NFAT activation in
C2C12 cells. A peptide matching the portion of the NFAT
protein that binds to calcineurin (SPRIEIT) was expressed
from a plasmid as a fusion protein attached to the amino
terminus of green fluorescent protein (Aramburu et al., 1998).
The control plasmid containing a mutant peptide that does not
interact with calcineurin (SPAIAIA) was also used in these
experiments. As before, caCn caused an increase in EmbWT
and PeriWT activity compared to the β-gal control plasmid
and co-transfection of caCn and SPAIAIA gave similar
activation of these two promoters (Figs. 6A and B). Co-
transfection of caCn along with the NFAT inhibitor, SPRIEIT,
caused a decrease in the activation level of PeriWT but not
EmbWT. An NFAT sensor expression construct containing
three tandem NFAT binding sites upstream of the luciferase
coding sequence was used as a control for caCn activation
and SPRIEIT inhibition and showed the expected responses
(Fig. 6C).Fig. 6. NFATandMEF2 contribution to promoter activation. The role of NFAT in caC
NFAT activation (SPRIEIT) and a control analog that has no inhibitory activity (SPA
same conditions. (D) Activity of a MyHC-peri construct with the conserved MEF2
**P = 0.0001.The importance of a putative MEF2 binding site in the
MyHC-peri promoter was also tested in C2C12 cells. The
conserved sequence located in the proximal region of the
promoter was mutated to abolish MEF2 binding. Activity of the
mutant promoter sequence was significantly decreased by over
60% relative to the wild-type promoter (Fig. 6D).
E-boxes are essential for expression
Each of the putative E-boxes (numbered 1–3 for each
promoter; Fig. 4) was individually mutated within the context of
the full EmbWT and PeriWT promoter sequences and tested in
cell culture. For each mutant construct, a pair of point mutations
was designed to change either the invariant CA or TG bases of
the E-box core sequence CANNTG. Mutation of E-box 2 or E-
box 3 resulted in a significant decrease in activity by 40–65%
compared to wild type for both promoters (Figs. 7A and B).
Simultaneous mutation of E-boxes 2 and 3 resulted in a further
decrease in activity to about 10% of the wild-type activity (Figs.
7A and B). Mutation of E-box 1 in these promoters resulted in a
slight but significant increase in activity, suggesting that this E-
box may bind a negative regulator (Figs. 7A and B).n activation of EmbWT (A) and PeriWT (B) is shown using a specific inhibitor of
IAIA). Panel C shows the activity of a control NFAT sensor plasmid under the
site mutated is compared to PeriWT. NS, not significantly different; *P < 0.05;
Fig. 7. Relative activity of wild-type and mutant promoters. (A) Fold change in promoter activity indicated by normalized luciferase activity for MyHC-emb E-box
mutant constructs compared to EmbWT. (B) Fold change in promoter activity indicated by normalized luciferase activity for MyHC-peri E-box mutant constructs
compared to PeriWT. *Significantly different from WT (P < 0.05); **significantly different from WT (P < 0.0001).
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along with a plasmid overexpressing MyoD to assess the role of
the binding sites in MyoD activation of these promoters (Fig. 8).
EmbWT and PeriWT were activated by MyoD in this
experiment by 28-fold and 6.5-fold, respectively. The embry-
onic double mutant (EE2/3) and triple mutant (EE1/2/3) showed
an approximately 55% decrease in activation by MyoD
compared to EmbWT (Fig. 8A). Five additional non-conserved
E-boxes in the mouse MyHC-emb promoter were also mutated,
and the construct containing no intact E-boxes was tested
(EnoE). This construct had activity 75% lower than EmbWT
(Fig. 8A). The only mutant MyHC-peri construct showing a
significant loss of MyoD activation was PE1/2/3 which
contained no intact E-boxes. PE1/2/3 was a modest 31% less
active than PeriWT (Fig. 8B). The original luciferase expression
plasmid containing the CMV promoter was activated almost 2-
fold by MyoD in L cells (Fig. 8).
A subset of E-boxes form complexes with myocyte nuclear
proteins
Duplex probes containing wild-type or mutant E-boxes from
the MyHC-emb and MyHC-peri promoters were used inmobility shift assays to determine the protein binding capability
of each sequence. The wild-type probes for MyHC-emb E-
boxes 2 and 3 (EE2 WT and EE3 WT) both formed two specific
complexes with components of C2C12 nuclear extract (Figs. 9C
and D). The corresponding mutant probes were unable to form
these complexes indicating that an intact E-box is necessary for
the binding of these complexes to the DNA (data not shown).
One or both of the complexes were supershifted by a MyoD-
specific antibody (Figs. 9C and D, lane Ab). The wild-type
probe for MyHC-emb E-box 1 (EE1 WT) also formed similar
complexes that were supershifted with MyoD antibody (Fig.
9A). While the faster mobility complex was not able to form
with the mutant probe, the slower mobility protein complexes
did show some binding ability and, therefore, are E-box
independent (Fig. 9B).
Despite decreased MyHC-peri promoter activity in response
to mutation of the proximal E-boxes (Fig. 7B), these sequences
do not appear to bind any of the MRFs. PE1 WT probe formed
many complexes with components of the C2C12 nuclear extract
(Fig. 9E); however, only the faster migrating complexes were
specific since they were not formed in the presence of an excess
of specific competitor (lane SC) and were also not present with
the mutant probe (data not shown). Two specific complexes
Fig. 8. Response of mutants to MyoD overexpression. Wild-type and E-box mutant constructs were co-transfected with a plasmid overexpressing MyoD or β-gal into
L cells. The induction of each promoter is shown relative to the promoter activity in the presence of β-galactosidase overexpression. Panel A shows embryonic MyHC
constructs. Panel B shows perinatal MyHC constructs. *Significantly different from WT (P < 0.005); †significantly different from EE2/3 and EE1/2/3 (P < 0.005).
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and data not shown). The PE3 WT probe formed three
complexes that were inhibited by a specific competitor, but
the complexes also formed with the PE3 mut probe indicating
that the complexes do not require the E-box sequence but rather
were binding to flanking sequences in the probe (Figs. 9G and
H). None of the complexes that contained either the PE1 WT
probe or the PE2 WT probe were supershifted by antibodies
specific for MyoD, Myf5, myogenin, or MRF4 (data not
shown). The PE1 WT probe also contained a putative NF1
binding site, but an antibody against NF1 also failed to
supershift any of the complexes (data not shown).
Promoter activity in vivo
One interesting aspect of developmental MyHC expression
is the downregulation of mRNA and protein after birth. This
aspect cannot be easily modeled in cell culture. To understand
the role of E-boxes 2 and 3 of the MyHC-emb and MyHC-peri
promoters in vivo, wild-type and mutant plasmid DNA
constructs were injected into the hindlimb of newborn mousepups or the tibialis anterior (TA) of 2-month-old mice. As
shown in Fig. 10A, activity of both wild-type promoters was
significantly higher at 5 dpn than at 2 months of age. This
corresponds to the time period when expression of the
endogenous genes decreases. To determine the role of E-
boxes in this developmental downregulation of expression,
mutants were tested at the same time points. Constructs with
double mutants have approximately 20% of the activity as wild
type at both ages tested (compare Figs. 10A and B), mirroring
our cell culture results. Also, double mutant constructs showed
a significant decrease in activity from 5 dpn to 2 months of age
indicating that these E-boxes are not required for the postnatal
decrease in expression (Fig. 10B).
Discussion
The pathways involved in regulating MyHC-emb and
MyHC-peri transcription have not been previously examined.
The results of this study implicate relatively short segments of
proximal promoter sequences in conferring high activity in
muscle cells to these two promoters. Further, we show that
Fig. 9. Electrophoretic mobility shift assay of wild-type and mutant E-boxes. Labeled probes containing E-boxes from MyHC-emb and MyHC-peri promoters were
incubated with a complex C2C12 nuclear extract and run on a non-denaturing gel. (A) MyHC-emb wild-type E-box 1, (B) MyHC-embmutant E-box 1, (C) MyHC-emb
wild-type E-box 2, (D) MyHC-emb wild-type E-box 3, (E) MyHC-peri wild-type E-box 1, (F) MyHC-peri wild-type E-box 2, (G) MyHC-peri wild-type E-box 3, (H)
MyHC-peri wild-type and mutant E-box 3. P, probe alone; PN, probe and C2C12 nuclear extract; SC, probe, extract, and 50× specific competitor; Ab, MyoD specific
antibody. Left arrows indicate bands that are both E-box dependent and competed by a specific competitor. Right arrows indicate supershifted bands.
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activation. While these promoters are induced largely by the
same molecules, the details of their transcriptional regulation
appear distinct.
In both of the developmental MyHC promoters, we have
identified an important region of 200–300 bp, each containing
three E-box elements (Figs. 4 and 5). Reporter constructs
containing mutations in either of the two proximal E-boxes had
lower activity relative to wild type, and mutations in both
proximal E-boxes revealed an additive decrease of promoter
activity (Figs. 7A and B). This suggests that both E-boxes are
necessary for full activity of the promoter. Injection of the wild-type and double mutant constructs into hindlimb muscle in vivo
indicates that these two E-boxes are also important for
expression in maturing muscle fibers (Fig. 10). Because of
greater variability in data from injection studies in general, the
difference between the PeriWT and PE2/3 constructs was not
significant at 5 dpn but shows the same trend as in cell culture.
Both wild-type and mutant sequences also exhibited lower
activity in adult mouse muscle than in newborn mouse muscle
(Fig. 10), indicating that these E-boxes are not required for the
postnatal downregulation of these genes.
The two proximal MyHC-emb E-boxes described here
correspond to two E-boxes found by Konig et al. (2002) in a
Fig. 10. Activity of wild-type and double mutant promoters in vivo. Wild-type (A) and E-box double mutant plasmid constructs (B) were injected into the hindlimb of 1
dpn mice or the tibialus anterior of 2-month-old mice and muscles were collected for luciferase assay 4 days later. Normalized (firefly/renilla) values are shown.
*Significantly different from same construct at 5 dpn (P < 0.05); †significantly different from wild type at same time point (P < 0.05).
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those researchers to bind MRFs (ChemE-2 E-boxes 5 and 6). In
their work, the authors describe a construct containing distal and
proximal regions of the human promoter that has activity similar
to their full length promoter (Konig et al., 2002). While the
sequences of these constructs cannot be directly compared to
our distal + min construct, the sequences that the Konig
construct contains that are absent in our construct appear to
include a conserved YY1 binding site and a conserved NF1 site.
These or other unidentified sequences may be playing an
important cooperative role in MyHC-emb transcription.
The distal E-box for both MyHC-emb and MyHC-peri also
showed similar characteristics. Mutations in either resulted in
slightly increased activity compared to the wild-type promoter
in cell culture (Figs. 7A and B). While none of the MRFs has
ever been shown to be inhibitory, an E-box in the MLC
enhancer binds to a complex that has a weak negative regulatory
role (Ceccarelli et al., 1999). The MLC enhancer E-box is not
transactivated by MyoD, but the EE1 site is able to bind a
complex that includes MyoD (Fig. 9A). Because the EE1 mut
probe binds a complex that does not bind the EE1 WT probe
(Figs. 9A and B), we may have created a binding site for an
activator. To examine this possibility, a different mutation of
embryonic E-box 1 was made (CATCTG to TCTCTG; EE1′) in
the context of the full length promoter and tested in cell culture.
The EE1′ construct also showed a slight increase in activity
compared to EmbWT (data not shown) making this scenario
unlikely. The PE1 WT probe formed two E-box-dependent,
sequence specific complexes, but neither of these complexes
was super-shifted with MRF antibodies (Fig. 9E and data not
shown). These complexes appear to contain unidentified E-box
binding proteins that suppress the transcription of the MyHC-
peri gene.
Overexpression studies in cell culture highlight other
similarities as well as differences between the mechanismsregulating MyHC-emb and MyHC-peri. Induction of both
promoters by constitutively active calcineurin is seen in muscle
cells and appears to require muscle specific factors that are not
present in fibroblastic L cells since caCn overexpression in
these cells had no effect on either promoter (Fig. 3). This is
consistent with the finding that a muscle environment is
necessary for caCn activation of other muscle genes (Chin et al.,
1998). Interestingly, although caCn was able to induce the
developmental MyHC promoters in muscle cells, the two best
characterized of calcineurin's downstream targets do not seem
to be driving this induction entirely (Fig. 3A). Overexpression
of constitutively nuclear NFATor of MEF2 caused no change in
promoter activity. However, when overexpressed together,
these two transcription factors were able to induce the
EmbWT construct (Fig. 3A). EmbWT was induced to the
same level by caCn in the presence of a peptide inhibitor of
NFAT and a control peptide (Fig. 6A), indicating that
calcineurin induction of this promoter is not mediated by
NFAT. This, taken together with the fact that there is no
apparent MEF2 binding site in the EmbWT promoter, suggests
that the slight induction we see with co-transfection of cnNFAT
and MEF2 is due to a secondary effect that may not have
relevance to endogenous conditions. In the case of MyHC-peri,
the combination of cnNFAT and MEF2 overexpression did not
increase promoter activity in C2C12 cells (Fig. 3A). However,
when caCn is co-transfected with an NFAT inhibitor, the
promoter's activity is diminished back to the basal level (Fig.
6B). The discrepancy between these results indicates that while
NFAT is a necessary mediator, additional downstream factors
are also required for the activation of MyHC-peri by caCn in a
muscle cell environment. The conserved MEF2 binding site
located in the proximal 360 bp of the promoter (Fig. 4) is also
important for PeriWT activity (Fig. 6D). At this time, other
calcineurin effectors that may be involved in the activation of
MyHC-peri transcription are unknown.
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similarities and differences between the two promoters. Myf5
and myogenin are the first MRFs to be expressed during
myogenesis and are the only ones present at the time that the
MyHC-emb transcript is first detected (Lyons et al., 1990; Ott et
al., 1991). Therefore, one might expect Myf5 or myogenin to be
involved in the activation of MyHC-emb transcription. Myf5
overexpression in C2C12 cells modestly but significantly
activated the EmbWT promoter by 1.3-fold (Fig. 3A), indicating
a possible role in the initiation of MyHC-emb transcription.
MyoD overexpression also induces activity of the MyHC-emb
promoter in muscle and non-muscle cell lines (Fig. 3). The
ability of MyoD to transform non-muscle cell types into muscle
(Choi et al., 1990; Davis et al., 1990; Tapscott et al., 1988)
dictates that the induction of theMyHC promoters in L cells may
be due to either direct binding of MyoD to the promoters or
indirect induction via a larger signaling network that is activated
by MyoD. Because the expression of MyoD trails MyHC-emb
expression by a day (Lyons et al., 1990; Ott et al., 1991), it is
possible that MyoD acts as an amplifying signal. In contrast, the
PeriWT promoter responded to MyoD overexpression but not to
Myf5 overexpression (Fig. 3A). MyoD may be the initiating
factor for MyHC-peri transcription because their onset of
expression coincides (Lyons et al., 1990; Ott et al., 1991).
The abilities of MRFs to bind the MyHC-emb and MyHC-
peri E-boxes were also distinct. The decreased activity of
promoters containing mutations in each of the two proximal E-
box mutants is consistent with the possibility of MRFs binding
to the promoter to induce expression. Surprisingly, only the
MyHC-emb proximal E-boxes formed complexes with MyoD
(Fig. 9). The MyHC-peri E-boxes failed to bind complexes
containing any of the MRFs. Because MRFs cooperate with
other family members as well as other transcription factors to
activate transcription, the complexes that bind the MyHC-peri
E-boxes likely require a co-factor that binds a sequence that is
present in the full-length promoter but is not present on the
probe used for binding assays. Alternatively, an MRF could be
activating at these binding sites but is not detectable using these
methods. This idea is supported by the fact that binding affinity
and transcriptional activation ability of MyoD are not always
correlated (Huang et al., 1996).
To understand whether MyoD induction of these promoters
is direct or indirect as well as to reconcile the lack of MRF
binding to MyHC-peri E-boxes, we performed co-transfection
experiments with E-box mutant constructs and the MyoD
overexpression plasmid in L cells (Fig. 8). In these experiments,
MyHC-emb E-boxes 2 and 3 show a clear role in activation by
MyoD. Mutation of additional E-boxes in the MyHC-emb
promoter decrease the activity further, indicating that MyoD
may also bind at one or more of these other sites to activate
transcription. In the case of MyHC-peri, all three of the
promoter's E-boxes must be mutated to diminish activation by
MyoD. Both of the developmental MyHC promoter constructs
with no intact E-boxes are still activated by MyoD to a higher
extent than the control plasmid with the same backbone
sequence. This activation is, therefore, likely via secondary
muscle-specific effects.The control of muscle transcription is a complex web of
cooperating factors from a number of pathways. The present data
suggest that the promoters of MyHC-emb and MyHC-peri are
controlled by members of the MRF family and the calcineurin
pathway. Based on the timing of MRF expression, we believe
Myf5 initiates the expression of MyHC-emb, while MyoD
enhances it. MyHC-peri is also activated by MyoD, though this
activation is mostly due to an indirect interaction. Calcineurin
also plays a role in the upregulation of both developmental
MyHCs. Some, but not all, of this regulation is mediated by
NFAT and MEF2 in the case of MyHC-peri, while activation of
MyHC-emb by calcineurin is not mediated by NFAT.
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